FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3094049503> ?p ?o ?g. }

• W3094049503 abstract "The aim of this study was to assess the relationship between serum vedolizumab (VDZ) concentrations and antibodies to VDZ (ATV) in a large cohort of patients with inflammatory bowel diseases. Furthermore, we evaluated the association between serum VDZ concentrations and a novel serum-based biomarker panel designated as the endoscopic healing index (EHI), developed and validated for identifying mucosal inflammation in patients with Crohn's disease (CD).Retrospective study where results from patient samples submitted to a commercial clinical laboratory were included. Serum VDZ and ATV levels were analyzed using a drug-tolerant assay. In CD patients for whom both VDZ and EHI were available, VDZ concentrations were correlated with EHI. serum VDZ threshold analysis was performed using ROC curves, and the serum VDZ concentrations that best differentiated EHI < 20 (previously associated with endoscopic remission) were chosen.A total of 9356 patients were included in the VDZ/ATV analysis. Detectable ATV was observed in 2.9% patients with significantly lower serum VDZ concentrations when compared to those with undetectable ATV [3.9 µg/mL (0-9.0) vs. 11.3 µg/mL (5.9-20.6), p < 0.0001]. Of the patients with serum VDZ result, 287 patients had a concomitant EHI test. An inverse correlation was observed between VDZ concentration and EHI (rho = - 0.20, p < 0.001). A serum VDZ concentration ≥ 15.7 µg/ml was best correlated wi th an EHI < 20 [AUROC: 0.67 (95% CI 0.57-0.77)].Incidence of ATVs was low, but significantly associated with lower VDZ levels. A serum VDZ concentration threshold of ≥ 15.7 µg/ml was associated with endoscopic remission as defined by an EHI < 20." @default.
• W3094049503 created "2020-10-29" @default.
• W3094049503 creator A5003590233 @default.
• W3094049503 creator A5009302642 @default.
• W3094049503 creator A5009375239 @default.
• W3094049503 creator A5032182315 @default.
• W3094049503 creator A5034738993 @default.
• W3094049503 creator A5052596220 @default.
• W3094049503 creator A5056035336 @default.
• W3094049503 creator A5082987648 @default.
• W3094049503 date "2020-10-22" @default.
• W3094049503 modified "2023-09-25" @default.
• W3094049503 title "Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases" @default.
• W3094049503 cites W2059843231 @default.
• W3094049503 cites W2077531651 @default.
• W3094049503 cites W2118559127 @default.
• W3094049503 cites W2145436896 @default.
• W3094049503 cites W2162805528 @default.
• W3094049503 cites W2195373199 @default.
• W3094049503 cites W2318120572 @default.
• W3094049503 cites W2328126238 @default.
• W3094049503 cites W2766230215 @default.
• W3094049503 cites W2773289068 @default.
• W3094049503 cites W2911819327 @default.
• W3094049503 cites W2912982848 @default.
• W3094049503 cites W2919105977 @default.
• W3094049503 cites W2984121388 @default.
• W3094049503 doi "https://doi.org/10.1007/s10620-020-06669-6" @default.
• W3094049503 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8449757" @default.
• W3094049503 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33089483" @default.
• W3094049503 hasPublicationYear "2020" @default.
• W3094049503 type Work @default.
• W3094049503 sameAs 3094049503 @default.
• W3094049503 citedByCount "1" @default.
• W3094049503 countsByYear W30940495032022 @default.
• W3094049503 crossrefType "journal-article" @default.
• W3094049503 hasAuthorship W3094049503A5003590233 @default.
• W3094049503 hasAuthorship W3094049503A5009302642 @default.
• W3094049503 hasAuthorship W3094049503A5009375239 @default.
• W3094049503 hasAuthorship W3094049503A5032182315 @default.
• W3094049503 hasAuthorship W3094049503A5034738993 @default.
• W3094049503 hasAuthorship W3094049503A5052596220 @default.
• W3094049503 hasAuthorship W3094049503A5056035336 @default.
• W3094049503 hasAuthorship W3094049503A5082987648 @default.
• W3094049503 hasBestOaLocation W30940495031 @default.
• W3094049503 hasConcept C112705442 @default.
• W3094049503 hasConcept C126322002 @default.
• W3094049503 hasConcept C2776207728 @default.
• W3094049503 hasConcept C2778260677 @default.
• W3094049503 hasConcept C2779134260 @default.
• W3094049503 hasConcept C2780272996 @default.
• W3094049503 hasConcept C71924100 @default.
• W3094049503 hasConcept C90924648 @default.
• W3094049503 hasConceptScore W3094049503C112705442 @default.
• W3094049503 hasConceptScore W3094049503C126322002 @default.
• W3094049503 hasConceptScore W3094049503C2776207728 @default.
• W3094049503 hasConceptScore W3094049503C2778260677 @default.
• W3094049503 hasConceptScore W3094049503C2779134260 @default.
• W3094049503 hasConceptScore W3094049503C2780272996 @default.
• W3094049503 hasConceptScore W3094049503C71924100 @default.
• W3094049503 hasConceptScore W3094049503C90924648 @default.
• W3094049503 hasLocation W30940495031 @default.
• W3094049503 hasLocation W30940495032 @default.
• W3094049503 hasLocation W30940495033 @default.
• W3094049503 hasLocation W30940495034 @default.
• W3094049503 hasOpenAccess W3094049503 @default.
• W3094049503 hasPrimaryLocation W30940495031 @default.
• W3094049503 hasRelatedWork W12793632 @default.
• W3094049503 hasRelatedWork W12824267 @default.
• W3094049503 hasRelatedWork W13849258 @default.
• W3094049503 hasRelatedWork W19273349 @default.
• W3094049503 hasRelatedWork W2087110 @default.
• W3094049503 hasRelatedWork W2509503 @default.
• W3094049503 hasRelatedWork W3199654 @default.
• W3094049503 hasRelatedWork W3359884 @default.
• W3094049503 hasRelatedWork W6037433 @default.
• W3094049503 hasRelatedWork W9449363 @default.
• W3094049503 isParatext "false" @default.
• W3094049503 isRetracted "false" @default.
• W3094049503 magId "3094049503" @default.
• W3094049503 workType "article" @default.